ViewRay, Inc. specializes in advanced radiation therapy systems, particularly the MRIdian system, which integrates MRI technology with radiation therapy for cancer treatment. The company operates primarily in the United States and Europe, targeting hospitals and cancer treatment centers that seek precision in radiation delivery.
Business Overview
ViewRay generates revenue primarily through the sale of its MRIdian systems, which are priced at approximately $4 million each, alongside recurring revenue from service contracts and consumables. The integration of MRI technology provides a unique competitive advantage, allowing for real-time imaging during treatment, which enhances precision and patient outcomes.
Regulatory approvals for new indications of the MRIdian system
Sales growth in international markets, particularly Europe and Asia
Partnerships with major cancer treatment centers
Technological advancements in radiation therapy
Risk Factors
Technological disruption from emerging radiation therapy technologies
Changes in healthcare regulations affecting reimbursement rates
Increased competition from established players like Varian and Elekta
Potential new entrants leveraging advanced technologies
High debt levels relative to equity, increasing financial risk
Negative cash flow impacting liquidity
Macro Sensitivity
moderate - The demand for cancer treatment technologies can be somewhat insulated from economic cycles, but capital expenditures by hospitals can be affected by economic downturns.
Higher interest rates could increase financing costs for hospitals purchasing equipment, potentially dampening demand for MRIdian systems.
minimal - The company does not heavily rely on credit for operations, but hospital financing conditions can indirectly affect sales.
Profile
growth - Investors looking for high-growth potential in innovative medical technologies.
high - The stock has exhibited significant price volatility, reflecting market sentiment and operational challenges.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
